372 related articles for article (PubMed ID: 23172669)
21. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
22. Type II ground-glass hepatocytes as a marker of hepatocellular carcinoma in chronic hepatitis B.
Mathai AM; Alexander J; Kuo FY; Torbenson M; Swanson PE; Yeh MM
Hum Pathol; 2013 Aug; 44(8):1665-71. PubMed ID: 23574780
[TBL] [Abstract][Full Text] [Related]
23. Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma.
Berg JP; Zhou Q; Breuhahn K; Schirmacher P; Patil MA; Chen X; Schäfer N; Höller TT; Fischer HP; Büttner R; Gütgemann I
Hum Pathol; 2007 Nov; 38(11):1621-7. PubMed ID: 17651785
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B virus PreS2-mutant large surface antigen activates store-operated calcium entry and promotes chromosome instability.
Yen TT; Yang A; Chiu WT; Li TN; Wang LH; Wu YH; Wang HC; Chen L; Wang WC; Huang W; Chang CW; Chang MD; Shen MR; Su IJ; Wang LH
Oncotarget; 2016 Apr; 7(17):23346-60. PubMed ID: 26992221
[TBL] [Abstract][Full Text] [Related]
25. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
28. Jun activation domain binding protein 1 is overexpressed from the very early stages of hepatocarcinogenesis.
Yachida S; Imaida K; Yokohira M; Hashimoto N; Suzuki S; Okano K; Wakabayashi H; Maeta H; Suzuki Y
Ann Surg Oncol; 2010 Dec; 17(12):3386-93. PubMed ID: 20589433
[TBL] [Abstract][Full Text] [Related]
29. Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication.
Sato A; Saito Y; Sugiyama K; Sakasegawa N; Muramatsu T; Fukuda S; Yoneya M; Kimura M; Ebinuma H; Hibi T; Ikeda M; Kato N; Saito H
J Cell Biochem; 2013 Sep; 114(9):1987-96. PubMed ID: 23519646
[TBL] [Abstract][Full Text] [Related]
30. Chemopreventive effect of Curcuma longa Linn on liver pathology in HBx transgenic mice.
Kim J; Ha HL; Moon HB; Lee YW; Cho CK; Yoo HS; Yu DY
Integr Cancer Ther; 2011 Jun; 10(2):168-77. PubMed ID: 21190953
[TBL] [Abstract][Full Text] [Related]
31. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
Tsai HW; Lin YJ; Wu HC; Chang TT; Wu IC; Cheng PN; Yen CJ; Chan SH; Huang W; Su IJ
Oncotarget; 2016 May; 7(19):27724-34. PubMed ID: 27027237
[TBL] [Abstract][Full Text] [Related]
32. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
33. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes.
Shi ZJ; Ouyang DY; Zhu JS; Xu LH; He XH
Int Immunopharmacol; 2012 Apr; 12(4):580-7. PubMed ID: 22369900
[TBL] [Abstract][Full Text] [Related]
35. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
36. Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.
Kunnimalaiyaan S; Sokolowski K; Gamblin TC; Kunnimalaiyaan M
Am J Surg; 2017 Apr; 213(4):645-651. PubMed ID: 28007318
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of pre-S mutations in patients with genotype C hepatitis B virus infection.
Choi MS; Kim DY; Lee DH; Lee JH; Koh KC; Paik SW; Rhee JC; Yoo BC
J Viral Hepat; 2007 Mar; 14(3):161-8. PubMed ID: 17305881
[TBL] [Abstract][Full Text] [Related]
38. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients.
Chen CH; Hung CH; Lee CM; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
Gastroenterology; 2007 Nov; 133(5):1466-74. PubMed ID: 17915220
[TBL] [Abstract][Full Text] [Related]
39. Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma.
Kao JH; Liu CJ; Jow GM; Chen PJ; Chen DS; Chen BF
Liver Int; 2012 Oct; 32(9):1373-81. PubMed ID: 22676233
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B virus X protein activates CD59 involving DNA binding and let-7i in protection of hepatoma and hepatic cells from complement attack.
Shan C; Zhang S; Cui W; You X; Kong G; Du Y; Qiu L; Ye L; Zhang X
Carcinogenesis; 2011 Aug; 32(8):1190-7. PubMed ID: 21665888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
